Genmab is an international biotech company with 23 years of experience in developing cutting-edge antibodies and antibody technology. Please join Anthony Mancini, Chief Operating Officer, and Ron Graybill, Vice President of Market Access of Genmab, as they discuss how Genmab is getting ready to move into the next phase of the development and commercialization of their next-generation antibody technologies and robust product portfolio by partnering with top-tier research and payer organizations.